Current Neuro-Oncology

Volume 28 Number 21
31 July 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 21, 31 July

Lau BC, Ajaero DP, Hoff BA, Pearson A, Sajjakulnukit P, Wadden J, Adam T, Ji S, Green AL, Nabavizadeh A, Cao Y, Aryal M, Upadhyaya S, Franson A, Galban S, Venneti S, Federowicz B, Shapiro MA, Stuhlmiller TJ, Lyssiotis C, Galban CJ, Parmar HA, Ibrahim M, Koschmann C.
Early increase in apparent diffusion coefficient predicts favorable response to Dordaviprone (ONC201) therapy in H3K27M-mutant diffuse midline glioma.
Neuro Oncol. 2026 Jul 21:noag164. doi: 10.1093/neuonc/noag164. PMID: 42482168. ˍ

Liang B, Weil M.
Corticosteroids in Glioblastoma Management: A Reconsideration of a 65-Year Practice.
J Clin Oncol. 2026 Jul 22:JCO2600191. doi: 10.1200/JCO-26-00191. PMID: 42485601. ˍ

Carriere PP, Haisraely O, Aaroe A, Ahmed K, Lewis R, Colson-Fearon D, Bolden M, Swanson TA, Beckham TH, Wang C, De B, Perni S, Tom MC, Li J, McGovern S, McAleer MF, Ghia A, Jiang W, Chung C, Grosshans D, Ballester L, Esquenazi Y, Kamiya-Matsuoka C, Yeboa DN.
Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology.
J Neurooncol. 2026 Jul 23;179(1):12. doi: 10.1007/s11060-026-05712-2. PMID: 42489814. ˍ

Sanderson E, Drummond K, Dowling A, Bennett I, Freilich R, Phillips C, Ahern E, Campbell D, Campbell R, Harrup R, Reeves S, Collins I, Jennens R, Joshi S, Gan H, Fay M, Lynam J, Lim LE, Rosenthal M, Dumas M, Gibbs P, Gately L.
Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns.
J Neurooncol. 2026 Jul 23;179(1):13. doi: 10.1007/s11060-026-05717-x. PMID: 42493681˰ ˍ

Liu H, Lun P, Zhao J, Sun P.
Development and External Validation of a Nomogram for Predicting the Survival Outcomes of Patients with Ki-67 Positive Grade 4 Diffuse Gliomas.
Turk Neurosurg. 2026 Jul 24;36(4):500-508. doi: 10.5137/1019-5149.JTN.47174-24.2. PMID: 42541774. ˍ

Ronsley R, Huang W, Rohlf E, Seidel K, Brown C, Beebe A, Rawlings-Rhea SD, Lindgren C, Sad T, Crotty EE, Leary SES, Thomsen A, Beckstrom AR, Holtzclaw SL, Hoeppner C, Hurst D, MacQuivey M, Goldstein HE, Browd SR, Hauptman JS, Lee A, Ojemann JG, Wright JN, Albert CM, Pinto N, Gustafson JA, Ho O, Pattabhi S, Summers C, Annesley C, Wendler JN, Gust J, Gardner RA, Park JR, Jensen MC, Vitanza NA.
Intracerebroventricular B7-H3-targeting CAR T cells for non-pontine DMG and recurrent/refractory pediatric CNS tumors: a phase 1 trial.
Neuro Oncol. 2026 Jul 25:noag171. doi: 10.1093/neuonc/noag171. PMID: 42503899. Trial registration ID: NCT04185038˰ ˍ

Kebir S, Oster C, Sharma S, Jekel L, Schmidt T, Grieger J, Cappello G, Kizina K, Lazaridis L, Rauschenbach L, Ahmadipour Y, Dammann P, Junker A, Keyvani K, Feldheim J, Pierscianek D, Scheffler B, Proescholdt M, Hau P, Grosu AL, Krex D, Sure U, Kleinschnitz C, Pöttgen C, Stuschke M, Glas M.
Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF).
BMC Cancer. 2026 Jul 27;26(1):912. doi: 10.1186/s12885-026-16613-y. PMID: 42538542. Trial registration ID: DRKS00016667. ˍ

Alex AT, Hassan SP, Benghiat H, Herbert L, Adamski J, Bailey S, Esler C, Brookes L, Bamber M, Koudou G, Waite K, Bennett J, Das A, Tsang DS.
Re-Irradiation in Pediatric Diffuse Midline Glioma: A Multi-Institutional Retrospective Study.
Pediatr Blood Cancer. 2026 Jul 29:e70498. doi: 10.1002/1545-5017.70498. PMID: 42527894. ˍ

Conrad CA, Hsu SH, Thapar N, Maher EA, Cloughesy TF, Colman H, Gilbert MR, Puduvalli VK, Madden T, Priebe W.
Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.
Neurooncol Adv. 2026 Jul 31;8(1):vdag150. doi: 10.1093/noajnl/vdag150. PMID: 42569309. ˍ